Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634581 | 0.80 | ALDH1A1 (0.65) | ALDH1A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL24853561 | 0.80 | CYP11B1 (0.50) | ALDH1A1L3MBTL1TDP1PKMCYP11B1 | |
| SCHEMBL2656708 | 0.79 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1TDP1CYP11B1MEN1 | |
| SCHEMBL15871699 | 0.76 | CYP11B1 (0.46) | ALDH1A1L3MBTL1TDP1PKMCYP11B1 | |
| SCHEMBL2643717 | 0.74 | PKM (0.65) | ALDH1A1L3MBTL1TDP1PKMCYP11B1 | |
| SCHEMBL3433837 | 0.74 | GAA (0.58) | ALDH1A1L3MBTL1TDP1PKMCYP11B1 | |
| SCHEMBL4024502 | 0.73 | MAPT (0.55) | ALDH1A1L3MBTL1PKMCYP11B1MEN1 | |
| SCHEMBL25828536 | 0.73 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1TDP1PKMCYP11B1 | |
| SCHEMBL15651209 | 0.73 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1PKMCYP11B1CHRNB2 | |
| SCHEMBL2276119 | 0.72 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1TDP1CYP11B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-9000181-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2015-04-07 | — | — | US | disclosed |
| US-9000181-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2015-04-07 | — | — | US | disclosed |
| EP-2627653-B1 | 3-AMINO-PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2245025-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2197849-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| US-20080146625-A1 | C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus | BERTHEL STEVEN JOSEPH | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, HK1, GCK | ALDH1A1 262/4885L3MBTL1 1069/4885TDP1 497/4885 |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ALDH1A1 3057/4885L3MBTL1 1789/4885TDP1 4435/4885 |
| US-20080146625-A1 | C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus | GCK, PC, PCK2 | ALDH1A1 757/4885L3MBTL1 3034/4885TDP1 3923/4885 |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | GLS, GCKR, HK1 | ALDH1A1 268/4885L3MBTL1 2183/4885TDP1 709/4885 |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ALDH1A1 2995/4885L3MBTL1 1523/4885TDP1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.